CompoAtlas

NOCICEPTOL CIRCULATION & JAMBES LEGERES

Food supplement declared in France, declaration No 2022-9-956, decision dated 13 September 2022

NOCICEPTOL CIRCULATION & JAMBES LEGERES, from LABORATOIRE POLIDIS, is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: Hibiscus sabdariffa 1,500 mg per day, Vitis vinifera 42 mg per day, Ribes nigrum 40 mg per day, Hamamelis virginiana 30 mg per day, Crataegus laevigata 20 mg per day. None of the rules we check flags an issue with its declared composition.

Brand
NOCICEPTOL
Food business operator placing the product on the market
LABORATOIRE POLIDIS
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Tablet
Daily dose
1
Intended populations
Pregnant women, Breastfeeding women, Men, Women
Not recommended (according to the manufacturer)
Adolescents (under 18), Children (under 12)

Declaration 269036, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Hibiscus sabdariffa L.FleurExtrait sec aqueux1,500 mg
Vitis vinifera L.FeuillePoudre (de plantes séchées ou broyées)42 mg
Ribes nigrum L.FeuilleExtrait sec aqueux40 mg
Hamamelis virginiana L.FeuilleExtrait sec aqueux30 mg
Crataegus laevigata (Poir.) DC.Sommités fleuriesPoudre (de plantes séchées ou broyées)20 mg
Syzygium aromaticum (L.) Merr. & L.M.PerryBouton floralPoudre (de plantes séchées ou broyées)20 mg
Tanacetum parthenium (L.) Sch.Bip.Parties aériennesExtrait sec hydroalcoolique20 mg
Vaccinium myrtillus L.FruitPoudre (de plantes séchées ou broyées)20 mg
Chrysanthellum indicum subsp. afroamericanum B.L.TurnerParties aériennesPoudre (de plantes séchées ou broyées)19 mg
Melissa officinalis L.FeuilleExtrait sec aqueux18 mg
Cupressus sempervirens L.Cône femellePoudre (de plantes séchées ou broyées)17 mg
Centella asiatica (L.) Urb.Parties aériennesExtrait sec aqueux13 mg
Sedum roseum (L.) Scop.RacineExtrait sec hydroalcoolique11 mg
Eleutherococcus senticosus (Rupr. et Maxim.) MaximRacineExtrait sec aqueux10 mg
Ganoderma lucidum(Curtis ex Fr.) P.Karst.CarpophoreExtrait sec hydroalcoolique10 mg

Additives

E414, E341, E470b

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Photograph the packaging

Label warnings

Les compléments alimentaires doivent être utilisés dans le cadre d’un mode de vie sain et ne se substituent pas à une alimentation variée et équilibrée. Réservé à l’adulte. Ne pas dépasser la dose journalière recommandée. Tenir hors de portée des jeunes enfants. Conserver à l’abri de la chaleur et de l’humidité. Ne pas dépasser la date limite d’utilisation.

Regulatory points

None of the rules we check applies to the declared ingredients.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Hamamelis virginiana L.
    Read the warning, when it applies and the studies cited

    WITCH HAZEL - HAMAMELIS VIRGINIANA Buccal and Oromucosal

    Route of administration: Buccal Oromucosal

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 27 February 2026

    WITCH HAZEL - HAMAMELIS VIRGINIANA Ophthalmic

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or persist (for) more than 2 days (EMA 2009).

    Sources cited by Health Canada (1)
    • EMA 2009: European Medicines Agency. Committee on Herbal Medicinal Products. Community Herbal Monograph on Hamamelis virginiana L., folium et cortex aut ramunculus destillatium. [Accessed 2026 February 3]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-hamamelis-virginiana-l-folium-cortex-aut-ramunculus-destillatum_en.pdf

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience eye pain, changes in vision, continued redness, or irritation of the eye (EMA 2009).

    Sources cited by Health Canada (1)
    • EMA 2009: European Medicines Agency. Committee on Herbal Medicinal Products. Community Herbal Monograph on Hamamelis virginiana L., folium et cortex aut ramunculus destillatium. [Accessed 2026 February 3]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-hamamelis-virginiana-l-folium-cortex-aut-ramunculus-destillatum_en.pdf

    Health Canada monograph dated 27 February 2026

    WITCH HAZEL -HAMAMELIS VIRGINIANA Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Barnes et al. 2007; ESCOP 2003).

    Sources cited by Health Canada (2)
    • Barnes J, Anderson LA, Philipson JD. 2007. Herbal Medicines, 3rd edition. London (GB): The Pharmaceutical Press.
    • ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. 2003. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.

    Known adverse reactions

    When using this product you may experience gastrointestinal discomfort/disturbances (Gardner and McGuffin 2013; ESCOP 2003; Berardi et al. 2002; Mills and Bone 2000).

    Sources cited by Health Canada (4)
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. 2002. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association.
    • ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. 2003. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Raton (FL): Taylor and Francis Group; 2013.
    • Mills S, Bone K. 2000. Principles and Practice of Phytotherapy. Toronto (ON): Churchill Livingstone.

    Health Canada monograph dated 27 February 2026

    WITCH HAZEL - HAMAMELIS VIRGINIANA Topical

    Cautions and warnings

    Condition of application: All products.

    For external use only.

    When using this product avoid contact with eyes. If contact occurs, rinse thoroughly with water.

    Keep out of reach of children. If swallowed, call a poison control centre or get medical help right away.

    Applies to products for use on minor wounds/burns/bruises/irritations/inflammations or on hemorrhoids.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen, last (for) more than 7 days.

    Applies to products for use on varicose veins.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Contraindications

    Applies to products for use on minor wounds/burns/bruises/irritations/inflammations.

    Do not use on deep or puncture wounds, animal bites or serious burns.

    Known adverse reactions

    Condition of application: All products.

    Stop use if a skin rash occurs (ESCOP 2003; Berardi et al. 2002; Mills and Bone 2000).

    Sources cited by Health Canada (3)
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
    • ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • Mills S, Bone K. Principles and Practice of Phytotherapy. Toronto (ON): Churchill Livingstone; 2000.

    Applies to products for use on hemorrhoids.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience bleeding.

    Health Canada monograph dated 27 February 2026

  • Crataegus laevigata (Poir.) DC.
    Read the warning, when it applies and the studies cited

    Hawthorn

    Route of administration: Oral (ESCOP 2009; Bradley 2006; Mills and Bone 2000)

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking cardiac glycosides (e.g., digoxin) or blood pressure or heart medications (Brinker 2010; Bradley 2006).

    Sources cited by Health Canada (2)
    • Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (GB): British Herbal Medicine Association; 2006.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have chest pain, irregular heartbeat, or shortness of breath.

    Health Canada monograph dated 31 July 2026

  • Tanacetum parthenium (L.) Sch.Bip.
    Read the warning, when it applies and the studies cited

    FEVERFEW - TANACETUM PARTHENIUM

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Biggs et al. 1982).

    Sources cited by Health Canada (2)
    • Biggs MJ, Johnson ES, Persaud NP, Ratcliffe DM. Platelet aggregation in patients using feverfew for migraine. Lancet 1982;320(8301):776. PubMed
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.

    Applies to products providing 250 mg or less of dried herb top and/or leaf, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/ physician before use if you are breastfeeding (Boon 2000).

    Sources cited by Health Canada (1)
    • Boon H. Feverfew. In: Chandler F, editor. Herbs: Everyday Reference for Health Professionals. Ottawa (ON): Canadian Pharmacists Association and the Canadian Medical Association; 2000.

    Contraindications

    Applies to products providing 250 mg or less of dried herb top and/or leaf, per day.

    Do not use if you are pregnant (Gardner and McGuffin 2013; Brinker 2010).

    Sources cited by Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Ration (FL): Taylor and Francis Group; 2013.

    Applies to products providing more than 250 mg of dried herb top and/or leaf, per day.

    Do not use if you are pregnant or breastfeeding (EMA 2020).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Condition of application: All products.

    Stop use if hypersensitivity/allergy occurs (EMA 2020; Paulsen et al. 2001; Hausen 1996).

    Sources cited by Health Canada (2)
    • Hausen BM. A 6-year experience with compositae mix. American Journal of Contact Dermatitis 1996;7(2):94-99. PubMed
    • Paulsen E, Anderson KE and Hausen BM. Sensitization and cross-reaction patterns in Danish Compositae-allergic patients. Contact Dermatitis 2001;45(4):197-204. PubMed

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    When using this product you may experience sore mouth, mouth ulcers and/or gastrointestinal discomfort/disturbances (EMA 2020; Gardner and McGuffin 2013; Murphy et al. 1988; Johnson et al. 1985).

    Sources cited by Health Canada (3)
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Ration (FL): Taylor and Francis Group; 2013.
    • Johnson ES, Kadam NP, Hylands DM, Hylands PJ. 1985. Efficacy of feverfew as prophylactic treatment of migraine. British Medical Journal 291(6495):569-573.
    • Murphy JJ, Heptinstall S, Mitchell JR. Randomized double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 1988;332(8604):189-192.

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 19 December 2025

  • Vaccinium myrtillus L.
    Read the warning, when it applies and the studies cited

    BILBERRY - VACCINIUM MYRTILLUS - Buccal

    Route of administration: Buccal (Blumenthal et al. 2000)

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 30 January 2026

    BILBERRY - VACCINIUM MYRTILLUS - Oral

    Route of administration: Oral (Blumenthal et al. 2000)

    Cautions and warnings

    Condition of application: Relief of diarrhea.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condition of application: Slowing the progression of disorders of the eye and to relieve symptoms related to non-complicated CVI.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen.

    Health Canada monograph dated 25 October 2024

  • Melissa officinalis L.
    Read the warning, when it applies and the studies cited

    LEMON BALM -MELISSA OFFICINALIS

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2014).

    Sources cited by Health Canada (1)
    • EMA 2014. European Medicines Agency. Melissae folium.. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 16 June2014. [Accessed 2023 October 27]. Available at: https://www.ema.europa.eu/en/medicines/herbal/melissae-folium

    When using this product exercise caution if you drive or use machinery as you may experience drowsiness (EMA 2014).

    Sources cited by Health Canada (1)
    • EMA 2014. European Medicines Agency. Melissae folium.. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 16 June2014. [Accessed 2023 October 27]. Available at: https://www.ema.europa.eu/en/medicines/herbal/melissae-folium

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 26 April 2024

  • Sedum roseum (L.) Scop.
    Read the warning, when it applies and the studies cited

    RHODIOLA - RHODIOLA ROSEA

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2024).

    Sources cited by Health Canada (1)
    • EMA 2024: 20 March 2024 EMA/HMPC/24177/2023 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Rhodiola rosea L., rhizoma et radix Final - Revision 1. Amsterdam (NL): European Medicines Agency, Science Medicines Health. [Accessed 2025 January 21]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-rhodiola-rosea-l-rhizoma-et-radix-revision-1_en.pdf

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking antidepressant medication, hormone replacement therapy (HRT) or birth control medication (HC 2018; Iovieno et al. 2011; Olsson et al. 2009; Brown et al. 2002).

    Sources cited by Health Canada (4)
    • Brown RP, Gerbarg PL, Ramazanov Z. Rhodiola rosea: A Phytomedicinal Overview. HerbalGram 2002;56:40-52.
    • HC 2018: Health Canada. Canada Vigilance Adverse Reaction Online Database. Ottawa (ON): Marketed Health Products Directorate, Health Canada. [Accessed 2025 January 21]. Available from: https://cvp-pcv.hc-sc.gc.ca/arq-rei/index-eng.jsp
    • Iovieno, N., Dalton, ED., Fava, M., Mischoulon, D. Second-tier natural antidepressants: review and critique. Journal of Affective Disorders 2011;130(3): 343-357.
    • SC 2018: Santé Canada. Base de données en ligne des effets indésirables de Canada Vigilance. Ottawa (ON): Direction des produits de santé commercialisés, Santé Canada. [Consulté le 21 janvier 2025]. Disponible à : https://cvp-pcv.hc-sc.gc.ca/arq-rei/switchlocale.do?lang=fr&url=t.search.recherche

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Contraindications

    Do not use if you have bipolar disorder or bipolar spectrum disorder (Iovieno et al. 2011; Winston and Maimes 2007; Brown et al. 2002).

    Sources cited by Health Canada (3)
    • Brown RP, Gerbarg PL, Ramazanov Z. Rhodiola rosea: A Phytomedicinal Overview. HerbalGram 2002;56:40-52.
    • Iovieno, N., Dalton, ED., Fava, M., Mischoulon, D. Second-tier natural antidepressants: review and critique. Journal of Affective Disorders 2011;130(3): 343-357.
    • Winston D, Maimes S. Adaptogens: Herbs for Strength, Stamina, and Stress Relief. Rochester (VT): Healing Arts Press, 2007.

    Known adverse reactions

    Stop use if you experience irritability or insomnia (Pizzorno and Murray 2006; Kelly 2001).

    Sources cited by Health Canada (2)
    • Kelly GS. Rhodiola rosea: A Possible Plant Adaptogen. Alternative Medicine Review 2001;6(3): 293-302. PubMed Review article
    • Pizzorno JE, Murray MT, editors. Textbook of Natural Medicine. 3rd edition, volume 1. St. Louis (MI): Churchill Livingstone Elsevier; 2006.

    Health Canada monograph dated 31 October 2025

  • Eleutherococcus senticosus (Rupr. et Maxim.) Maxim
    Read the warning, when it applies and the studies cited

    ELEUTHERO - ELEUTHEROCOCCUS SENTICOSUS

    Route of administration: Oral (ESCOP 2003; Bradley 1992)

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Barnes et al. 2007; ESCOP 2003).

    Sources cited by Health Canada (2)
    • Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have an acute infection (Brinker 2010; Mills and Bone 2000).

    Sources cited by Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Mills S, Bone K. Principles and Practice of Phytotherapy. Toronto (ON): Churchill Livingstone; 2000.

    Contraindications

    Do not use if you have high blood pressure (Gardner and McGuffin 2013; Brinker 2010; Barnes et al. 2007; Blumenthal et al. 2000; Mills and Bone 2000).

    Sources cited by Health Canada (5)
    • Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
    • Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. 2nd edition. Boca Ration (FL): Taylor and Francis Group; 2013.
    • Mills S, Bone K. Principles and Practice of Phytotherapy. Toronto (ON): Churchill Livingstone; 2000.

    Health Canada monograph dated 31 October 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Brand : NOCICEPTOL

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “NOCICEPTOL CIRCULATION & JAMBES LEGERES: composition and regulation”, https://compoatlas.com/en/supplements/products/269036-nociceptol-circulation-jambes-legeres, updated 15 November 2026.

List recorded in 2022. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line